elzovantinib
turning point therapeutics
['lung', 'tpx-0022']
important work from showing that some lung cancers have actionable met tyrosine kinase domain mutations (different from metex14!) that can respond to the met inhibitor tpx-0022. #asco22 
Clinical Director, Director of Clinical Research, Associate Professor, Thoracic Oncology @DanaFarber | Lung Cancer Immunotherapy Research | Tweets my own